Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 828 across all filing types
Latest filing 2023-11-23 Report Publication Anno…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document explicitly states, "Adocia publishes its Letter to Shareholders" and provides a link to access the "November 2023 Letter to Shareholders." This is an announcement about the release of a specific shareholder communication document. Since 'Letter to Shareholders' is a form of direct communication to investors, and the document itself is short (3328 chars) and primarily serves to announce the availability of the actual letter (Menu vs Meal Rule), it fits best under the category for general investor communications or announcements. While 'LTR' (Legal Proceedings Report) is incorrect, and 'DEF 14A' (Remuneration) is incorrect, the closest fit for a general shareholder letter announcement that isn't a formal regulatory filing like 10-K or a specific financial report is often categorized as a general Investor Presentation (IP) or, given the context of announcing a publication, a Report Publication Announcement (RPA). However, since the content is specifically a 'Letter to Shareholders,' which is a direct communication, and it is being announced, 'IP' (Investor Presentation) is often used for detailed investor materials, but 'RPA' (Report Publication Announcement) perfectly describes the action taken by the company: announcing the publication of a report. Given the options, and the nature of announcing a specific document release, RPA is the most accurate classification for this announcement.
2023-11-23 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Mise à Disposition de la Lettre aux Actionnaires" (Making Available the Letter to Shareholders) and explicitly states that the 'Lettre aux Actionnaires de novembre 2023' is being made available, providing a link to access it. The document itself is very short (3857 characters) and functions primarily as an announcement that another document (the Letter to Shareholders) is ready for viewing. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the report itself.
2023-11-23 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled as a 'PRESS RELEASE' and its content focuses on disclosing the 'Total number of outstanding shares as well as its voting rights as of October 31st, 2023', citing French regulatory requirements (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter). This type of mandatory disclosure regarding share capital structure and voting rights, especially when issued as a press release detailing specific figures for a reporting date, most closely aligns with notifications about capital structure changes or major shareholding changes. Since it is a formal announcement of the current share count and voting rights, it relates to the company's capital structure. The closest specific category is 'Share Issue/Capital Change' (SHA), although it is a periodic disclosure of the current state rather than an announcement of a new issue. However, given the options, 'Major Shareholding Notification' (MRQ) is for changes in *ownership levels* crossing thresholds, and 'Share Issue/Capital Change' (SHA) covers capital structure announcements. Since this is a mandatory disclosure of the total share count, it is a fundamental capital structure update. If none of the specific categories fit perfectly, 'Regulatory Filings' (RNS) is the fallback. Because it is a specific, periodic disclosure mandated by financial authorities regarding the capital base, and not a general regulatory filing, I will evaluate against MRQ and SHA. It is not a transaction (POS) or a financing event (CAP). It is a statement of the current capital base. Given the options, and recognizing this is a mandatory disclosure of share count, it fits best under the general umbrella of capital structure reporting, making SHA a plausible fit, but it is often categorized as a general regulatory update when specific shareholding changes aren't the focus. Since it is a formal, periodic disclosure mandated by the AMF, and it doesn't fit the definitions of ER, IR, 10-K, or DIV, the most appropriate general category for mandatory, non-financial report disclosures is RNS, or if it relates to capital, SHA. Given the focus on the *number of shares* and *voting rights*, it is a capital structure notification. I will classify it as RNS as it is a general regulatory announcement that doesn't perfectly match the other specific capital/share categories (like POS or SHA which imply an *action*). It is a mandatory disclosure of current state, which often defaults to RNS if not covered elsewhere.
2023-11-15 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information relative au nombre d'actions et de droits de vote en date du 31 octobre 2023" and explicitly references French regulatory articles (Code de Commerce and AMF regulations) for publishing the total number of shares and voting rights. This type of periodic disclosure regarding capital structure changes or share counts, often triggered by crossing thresholds or required monthly/periodically, is a specific type of regulatory announcement. While it relates to capital structure, it is not a formal share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory disclosure of the current share count and voting power. Given the options, this specific disclosure about the total number of shares and voting rights, mandated by financial market authorities (AMF), fits best under the general category of regulatory filings that aren't covered by the more specific financial report types. However, since it directly concerns the number of shares and voting rights, it is closely related to capital structure changes. In many databases, mandatory disclosures of share counts are often categorized separately or as general regulatory filings. Since the document is a formal, periodic regulatory update concerning the capital base (shares and voting rights), and it is not a full financial report (10-K, IR) or a specific transaction announcement (SHA, POS), it falls under the general regulatory announcement category, RNS, as it is a mandatory filing with the AMF that doesn't fit the other specific financial report codes. If a more specific code existed for 'Share Capital Disclosure', that would be preferred, but RNS serves as the best fit for mandatory, non-financial report regulatory updates.
2023-11-15 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release announcing promising preclinical data for a therapeutic product (AdoShell® Islets) presented at scientific congresses (ADA, EASD, IPITA-IXA-CTRMS). It details scientific findings, preclinical results, and future clinical perspectives, including interactions with the EMA. This type of announcement, focusing on scientific/clinical progress and business outlook, is characteristic of an Investor Presentation (IP) or a general press release about research findings. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific announcement like a dividend (DIV) or management change (MANG), and it functions as a detailed update for investors and the scientific community, 'Investor Presentation' (IP) is the most fitting category, although it is structured as a press release. Given the detailed scientific and business update, IP is preferred over the general 'RNS' fallback. The length (9017 chars) confirms it is substantial content, not just a brief announcement of a report.
2023-11-09 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces scientific data regarding Adocia's AdoShell® Islets technology for diabetes treatment, referencing presentations at scientific congresses (ADA, EASD, IPITA-IXA-CTRMS). It details preclinical results, future clinical plans (EMA interaction, potential human trials by end of 2024), and provides company background. This format—a formal announcement of recent scientific/clinical progress and business outlook, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general press release detailing operational updates. Since it focuses on announcing key results and progress rather than being a full, comprehensive financial report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as these releases often contain operational and scientific highlights alongside financial context, or in this case, significant R&D milestones that drive investor interest. It is not a transcript (CT), a formal annual report (10-K), or a specific regulatory filing like DIRS or DIV. Given the focus on announcing results and progress, ER fits best, although RNS (Regulatory Filings) is a possibility if ER is too specific. However, the content strongly suggests an announcement of key performance/development milestones, aligning with the spirit of an ER. FY 2023
2023-11-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.